Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2001-03-30
2002-12-17
Berch, Mark L. (Department: 1624)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C544S319000, C544S320000, C544S268000, C544S284000, C544S250000, C546S080000, C546S089000, C514S291000, C514S265100, C514S267000, C514S269000
Reexamination Certificate
active
06495555
ABSTRACT:
The present invention concerns tricyclic &Dgr;3-piperidines having central &agr;
2
-adrenoceptor antagonist activity. It further relates to their preparation, compositions comprising them and their use as a medicine.
Central &agr;
2
-adrenoceptor antagonists are known to increase noradrenaline release by blocking presynaptic &agr;
2
-receptors which exert an inhibiting control over the release of the neurotransmitter. By increasing the noradrenaline concentrations, &agr;
2
-antagonists can be used clinically for the treatment or prophylaxis of depression, cognitive disturbances, Parkinson's disease, diabetes mellitus, sexual dysfunction and impotence, elevated intraocular pressure, and diseases related to disturbed enterokinesia, since all these conditions are associated with a deficiency of noradrenaline in the central or peripheral nervous system.
The compounds of the present invention are novel and have a specific and selective binding affinity for the different known subtypes of the &agr;
2
-adrenoceptors, i.e. the &agr;
2
A, &agr;
2
B and &agr;
2
C-adrenoceptor.
The present invention concerns the compounds of formula
the N-oxide forms, the pharmaceutically acceptable addition salts and the stereochemically isomeric forms thereof, wherein:
Alk is C
1-6
alkanediyl;
n is 1 or 2;
X
1
is —O—, —S—, —S(═O)— or —S(═O)
2
—;
each R
1
is independently hydrogen, halogen, C
1-6
alkyl, nitro, hydroxy or
C
1-4
alkyloxy;
D is a radical of formula
wherein
each m independently is 0, 1 or 2;
X
2
is —O— or —NR
11
—;
each X
3
independently is —O—, —S— or —NR
11
—;
X
4
is —O—, —S—, —CH
2
—S— or —NR
12
—;
X
5
and X
6
each independently are —CH
2
—, —O—, —S— or —NR
11
—;
R
2
is hydrogen, C
1-6
alkyl, aryl or arylC
1-6
alkyl;
R
3
is hydrogen, C
1-6
alkyl, C
1-6
alkyloxy, C
1-6
alkylthio, amino or mono- or di(C
1-6
alkyl)amino;
R
4
, R
5
, R
6
, R
7
, R
8
, R
9
, R
10
, R
11
and R
15
each independently are hydrogen or C
1-6
alkyl;
R
12
is hydrogen, C
1-6
alkyl, C
1-6
alkyloxyC
1-6
alkyl or pyridinylC
1-6
alkyl;
R
13
, R
14
sand R
16
each independently are halo or C
1-6
alkyl;
R
3
and R
4
taken together may form a bivalent radical —R
3
—R
4
— of formula
—CH
2
—CH
2
—CH
2
— (a-1);
—CH
2
—CH
2
—CH
2
—CH
2
— (a-2);
—CH═CH—CH
2
— (a-3);
—CH
2
—CH═CH— (a-4) or
—CH═CH—CH═CH— (a-5);
wherein one or two hydrogen atoms of said radicals (a-1) to (a-5) each independently may be replaced by halo, C
1-6
alkyl, arylC
1-6
alkyl, trifluoromethyl, amino, hydroxy, C
1-6
alalkyloxy or C
1-10
alkylcarbonyloxy; or
where possible, two geminal hydrogen atoms may be replaced by C
1-6
alalkylidene or arylC
1-6
alkylidene; or
—R
3
—R
4
— may also be
—S—CH
2
—CH
2
— (a-6);
—S—CH
2
—CH
2
—CH
2
— (a-7);
—S—CH═CH— (a-9);
—NH—CH
2
—CH
2
— (a-9);
—NH—CH
2
—CH
2
—CH
2
— (a-10);
—NH—CH═CH— (a-11);
—NH—CH═N— (a-12);
—S—CH═N— (a-13) or
—CH═CH—O— (a-14);
wherein one or where possible two or three hydrogen atoms in said radicals (a-6) to (a-14) each independently may be replaced by C
1-6
alkyl or aryl; and
aryl is phenyl or phenyl substituted with one, two or three substituents selected from halo, hydroxy, nitro, cyano, trifluoromethyl, C
1-6
alkyl, C
1-6
alkyloxy, C
1-6
alkylthio, mercapto, amino, mono- and di(C
1-6
alkyl)amino, carboxyl, C
1-6
alkyloxycarbonyl and C
1-6
alkylcarbonyl.
As used in the foregoing definitions the term halogen is generic to fluoro, chloro, bromo and iodo. The term C
1-4
alkyl defines straight and branched saturated hydro-carbons, having from 1 to 4 carbon atoms such as, for example, methyl, ethyl, propyl, butyl, 1-methylethyl, 1,1-dimethylethyl, 2-methylpropyl and the like. The term C
1-6
alkyl is meant to include C
1-4
alkyl radicals and the higher homologues thereof having 5 or 6 carbon atoms such as, for example, pentyl, hexyl and the like. The term C
1-10
alkyl is meant to include C
1-6
alkyl radicals and the higher homologues thereof having 7 to 10 carbon atoms such as, for example, heptyl, octyl, nonyl, decyl and the like. The term C
1-5
alkanediyl defines bivalent straight or branch chained alkanediyl radicals having from 1 to 5 carbon atoms such as, for example, methylene, 1,2-ethane-diyl, 1,3-propanediyl, 1,4-butanediyl, 1,5-pentanediyl and the like. C
1-6
alkanediyl is meant to include C
1-5
alkanediyl and the higher homologue thereof havin 6 carbon atoms such as 1,6-hexanediyl and the like. The term C
1-6
alkylidene defines bivalent straight or branch chained alkylidene radicals having from 1 to 6 carbon atoms such as, for example, methylene, ethylidene, 1-propylidene, 1-butylidene, 1-pentylidene, 1-hexylidene and the like.
The addition salts as mentioned herein are meant to comprise the therapeutically active addition salt forms which the compounds of formula (I) are able to form with appropriate acids, such as, for example, inorganic acids such as hydrohalic acids, e.g. hydrochloric or hydrobromic acid; sulfuric; nitric; phosphoric and the like acids; or organic acids such as, for example, acetic, propanoic, hydroxyacetic, lactic, pyruvic, oxalic, malonic, succinic, maleic, fumaric, malic, tartaric, citric, methanesulfonic, ethanesulfonic, benzenesulfonic, p-toluenesulfonic, cyclamic, salicylic, p-aminosalicylic, pamoic and the like acids.
The pharmaceutically acceptable addition salts as mentioned hereinabove are also meant to comprise the therapeutically active non-toxic base, in particular, a metal or amine addition salt forms which the compounds of formula (I) are able to form. Said salts can conveniently be obtained by treating the compounds of formula (I) containing acidic hydrogen atoms with appropriate organic and inorganic bases such as, for example, the ammonium salts, the alkali and earth alkaline metal salts, e.g. the lithium, sodium, potassium, magnesium, calcium salts and the like, salts with organic bases, e.g. the benzathine, N-methyl-D-glucamine, hydrabamine salts, and salts with amino acids such as, for example, arginine, lysine and the like. Conversely said salt forms can be converted by treatment with an appropriate base or acid into the free acid or base form.
The term addition salt as used hereinabove also comprises the solvates which the compounds of formula (I) are able to form and said solvates are meant to be included within the scope of the present invention. Examples of such solvates are, e.g. the hydrates, alcoholates and the like.
The N-oxide forms of the compounds of formula (I) are meant to comprise those compounds of formula (I) wherein one or several nitrogen atoms are oxidized to the so-called N-oxide.
The term stereochemically isomeric forms as used herein defines all the possible isomeric forms in which the compounds of formula (I) may occur. Unless otherwise mentioned or indicated, the chemical designation of compounds denotes the mixture of all possible stereochemically isomeric forms, said mixtures containing all diastereomers and enantiomers of the basic molecular structure.
Some of the compounds of formula (I) may also exist in their tautomeric forms. Such forms although not explicitly indicated in the above formula are intended to be included within the scope of the present invention.
As used hereinafter, when the position of the R
1
substitutent is referred to, the following numbering is used:
Whenever used hereinafter, the term compounds of formula (I) is meant to include also the N-oxide forms, the pharmaceutically acceptable addition salts and all stereoisomeric forms.
Special compounds are those compounds of formula (I) wherein D is a radical of formula (a), (b), (c), (d), (e), (f), (g), (h), (i), (j), (k) or (I); m is 0; and aryl is phenyl or phenyl substituted with halo or C
1-6
alkyl.
An interesting group of compounds are those compounds of formula (I) wherein n is 1 and R
1
is hydrogen, chloro, fluoro, methyl, methoxy or nitro, in particular R
1
is hydrogen, chloro, fluoro, methyl or methoxy.
In case R
1
is ot
Kennis Ludo Edmond Josephine
Mertens Josephus Carolus
Van den Keybus Frans Maria Alfons
Berch Mark L.
Habte Kahsay
Janssen Pharmaceutica N.V.
Woodcock & Washburn LLP
LandOfFree
Tricyclic &Dgr;-3-piperidines as &agr;2-antagonists does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Tricyclic &Dgr;-3-piperidines as &agr;2-antagonists, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Tricyclic &Dgr;-3-piperidines as &agr;2-antagonists will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2935914